ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1816

Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis

Brianna Lally1, Shudan Wang2, Sammy Chalmers3, Wenzhu Mowrey3, Tamar Rubinstein4, Beatrice Goilav5 and Anna Broder6, 1Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine, New York, NY, 3Albert Einstein College of Medicine, Bronx, 4Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY, 5The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 6Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

Meeting: ACR Convergence 2020

Keywords: Biomarkers, Disease Activity, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2020

Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Tubulointerstitial disease (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy (IFTA), is associated with progression to end stage renal disease (ESRD) in lupus nephritis. Early detection of TID via non-invasive methods is crucial to identifying those at highest risk for renal failure. A set of urine biomarkers of tubular damage has recently been developed to detect acute kidney injury.1 This study sought to determine whether these biomarkers of tubular injury collected around the time of clinically indicated biopsies for lupus nephritis were associated with the presence of IFTA/TII.

Methods: Urine samples from 29 adult and pediatric lupus patients with clinically indicated renal biopsies performed between 2010 and 2019 were included. Samples were evaluated for tubular injury markers KIM-1, interleukin-18 (IL-18), clusterin, calbindin, and glutathione S-transferase-π (GST- π) using the Bio-Plex ProTM kidney assay. Biomarkers (Table 1) were correlated with presence or absence of IFTA/TII on biopsies performed within 180 days prior to and 21 days after sampling. These biomarkers were normalized to urine creatinine excretion.

Results: Of 29 patients, 18 (62%) had evidence of IFTA on renal biopsy (Table 2). IFTA+ patients had a median age (IQR) of 36 (27, 50) vs. 20 (14, 59) in the IFTA group, p = 0.25. BMI was significantly higher in IFTA+ patients (median (IQR) 30 (24, 36) kg/m2 vs. 23 (20, 26) kg/m2, p < 0.001), as was blood pressure on day of biopsy. KIM-1 levels were higher when IFTA was present, median (IQR) 0.5 (0, 2) ng/mg vs. 0 (0, 0) ng/mg for IFTA+ and IFTA-, respectively, one sided p-value 0.04. KIM-1 was detectable ( > 0) in 9 (50%) of IFTA+ and in 2 (18%) IFTA-, p = 0.09. No association between KIM-1 and TII was observed. There was no association between the other 4 biomarkers and IFTA or TII (Table 3). KIM-1 levels did not differ by age, sex, race, ethnicity, or lupus nephritis class, and were not associated with serum C3, C4, or dsDNA at time of sample collection. KIM-1, calbindin, GST-π and clusterin were associated with proteinuria.

Conclusion: Though limited by sample size, these pilot results suggest that urinary KIM-1, a kidney injury marker secreted by the proximal tubules, in samples collected around the time of biopsies may serve as a non-invasive biomarker for the presence of IFTA in lupus nephritis.

Reference:

  1. Stephen L, et al. Profiling of Human, Canine, and Rat Urine Samples Using Bio-Plex ProTM RBM Kidney Toxicity Assays. Available from: http://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_6400.pdf


Disclosure: B. Lally, None; S. Wang, None; S. Chalmers, None; W. Mowrey, None; T. Rubinstein, None; B. Goilav, None; A. Broder, None.

To cite this abstract in AMA style:

Lally B, Wang S, Chalmers S, Mowrey W, Rubinstein T, Goilav B, Broder A. Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/urine-biomarkers-of-tubulointersitital-damage-in-lupus-nephritis/. Accessed April 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urine-biomarkers-of-tubulointersitital-damage-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.